EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adherence to Antipsychotics, COVID-19 and Stigma: A Rainbow After the Storm?

Luiz Dratcu, Xavier Boland

Actas Españolas de Psiquiatría · 2025

DOI: 10.62641/aep.v53i3.1813 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Actas Españolas de Psiquiatría, 2025. Verfasst von Luiz Dratcu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Acute Inpatient Psychiatry, Maudsley Hospital, South London and Maudsley NHS Foundation Trust, SE5 8AZ London, UK. Hauptthemen laut MEDLINE: COVID-19, Antipsychotic Agents, Social Stigma, Medication Adherence. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poor adherence to antipsychotic treatment is the main reason for relapse and admission in patients with severe mental illness (SMI). In addition to apprehensions about side effects, factors for non-adherence include the stigma of mental illness, which also extends to its treatment and which is further compounded by negative perceptions of antipsychotics within the medical profession itself. By reinforcing misconceptions around antipsychotics, warnings at the outbreak of pandemic associating antipsychotic use with coronavirus disease 2019 (COVID-19) related risks could have discouraged antipsychotic prescribing when it was otherwise indicated and also disrupted adherence of SMI patients to the treatment they need. Several studies on risk of antipsychotic use during the pandemic adopted inappropriate inclusion criteria and reached conclusions that proved misleading, particularly if applied to SMI patients. Methodological flaws included ill-defined cohort groups and not accounting for adherence to treatment or clinical indication for antipsychotic prescribing. Conversely, reports from the clinical setting, which were later corroborated in clinical studies, have shown that adherence to antipsychotics may actually protect from COVID-19, thus indicating that the benefits of adhering to antipsychotic treatment extend beyond controlling psychotic symptoms alone. Evidence emerging from the COVID-19 experience adds to the view that adherence to second generation antipsychotics in SMI offers a therapeutic effect to both mental and physical health. This validation of modern antipsychotics as a vital medical asset can prove a turning point in the fight to dispel the stigma of SMI and its treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antipsychotic AgentsSocial StigmaMedication AdherenceMental DisordersPsychotic DisordersHumans

Substanzen

Antipsychotic Agents

Autor:innen und Institutionen

  • Acute Inpatient Psychiatry, Maudsley Hospital, South London and Maudsley NHS Foundation Trust, SE5 8AZ London, UK.
  • Liaison Psychiatry Service, Lewisham Hospital, South London and Maudsley NHS Foundation Trust, SE5 8AZ London, UK.

Zitieren

APA

Dratcu, L., & Boland, X. (2025). Adherence to Antipsychotics, COVID-19 and Stigma: A Rainbow After the Storm?. Actas Españolas de Psiquiatría. https://doi.org/10.62641/aep.v53i3.1813

Vancouver

Dratcu L, Boland X. Adherence to Antipsychotics, COVID-19 and Stigma: A Rainbow After the Storm?. Actas Españolas de Psiquiatría. 2025. doi:10.62641/aep.v53i3.1813

BibTeX
@article{Dratcu2025,
  author = {Dratcu, Luiz and Boland, Xavier},
  title = {Adherence to Antipsychotics, COVID-19 and Stigma: A Rainbow After the Storm?},
  journal = {Actas Españolas de Psiquiatría},
  year = {2025},
  doi = {10.62641/aep.v53i3.1813}
}
Kostenlos starten →